 We wish to test new ligands currently being developed in our chemistry group by obtaining blood samples from additional PBR28 nonbinders low affinity binders and by performing in vitro binding assays. Because our preliminary analysis of whole body imaging has shown that the differences between PBR28 binders and nonbinders might somewhat vary among organs and the cause of the nonbinding phenomenon is not fully understood, after identifying PBR28 nonbinders by binding assays, we will perform whole body imaging using 11CPBR28. 